A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)

Description

This is a first in human, Phase 1/2 open-label multi-center, dose escalation and expansion study to evaluate the safety, tolerability, PK, PD and efficacy of RNK05047 when administered an intravenous (IV) infusion to subjects with advanced solid tumors, including diffuse large B-cell lymphoma (DLBCL). This is a 2-part study (dose escalation, cohort expansion) with sequential enrollment.

Conditions

Advanced Solid Tumor, DLBCL

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a first in human, Phase 1/2 open-label multi-center, dose escalation and expansion study to evaluate the safety, tolerability, PK, PD and efficacy of RNK05047 when administered an intravenous (IV) infusion to subjects with advanced solid tumors, including diffuse large B-cell lymphoma (DLBCL). This is a 2-part study (dose escalation, cohort expansion) with sequential enrollment.

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Chaperone-mediated Protein Degrader RNK05047 in Subjects With Advanced Solid Tumors (CHAMP-1)

A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)

Condition
Advanced Solid Tumor
Intervention / Treatment

-

Contacts and Locations

Atlanta

Emory University Winship Cancer Institute, Atlanta, Georgia, United States, 30322

Louisville

Norton Cancer Institute, Louisville, Kentucky, United States, 40202

New York

Weill Cornell - NY Presbyterian Hospital, New York, New York, United States, 10065

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Pathologically documented locally advanced or metastatic solid tumor
  • * Refractory or intolerant to all available standard-of-care therapies for advanced disease
  • * Measurable disease
  • * Archived tumor tissue collected
  • * ECOG Performance Status of 0 or 1
  • * BMI ≥ 18 kg/m2
  • * Adequate liver, renal, hematologic, and coagulation parameters
  • * Negative serum pregnancy test (for women of childbearing potential) at Screening and a negative urine or serum pregnancy test on Day 1 prior to the first infusion
  • * Males and females of childbearing potential must agree to use a highly effective method of contraception during treatment and for at least 4 months after the last dose of study treatment.
  • * Must be able to understand and comply with the conditions of the protocol and must have read and understood the consent form and provided written informed consent.
  • * Concurrent anticancer therapy: Radiotherapy, chemotherapy, biological therapy, or other anticancer investigational agents NOTE: at least 5 half-lives must have been ensued for any prior systemic cancer therapy agent before subject received the study drug on Day 1
  • * Unresolved toxicities from prior anticancer therapy, defined as not having resolved according to CTCAE version 5.0 Grade ≤ 1, excluding Grade 1 alopecia
  • * Presence or suspicion of active central nervous system (CNS) metastases and/or leptomeningeal carcinomatosis
  • * Peripheral neurotoxicity ≥ Grade 2 according to CTCAE v5.0
  • * Known active infection with HIV, HTLV-1, hepatitis B or C
  • * Women who are pregnant or breastfeeding
  • * History of another malignancy unless the subject has been treated with curative intent for this malignancy

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Ranok Therapeutics (Hangzhou) Co., Ltd.,

Linda Grummer, STUDY_DIRECTOR, Ranok Therapeutics

Study Record Dates

2025-03